Cisplatin for injection

This product is a metal complex of platinum, and its action is similar to that of an alkylating agent. Its main target is DNA, and it acts on the cross-links between DNA chains and within the chains to form a DDP-DNA complex, interfering with DNA replication, or binding to nuclear and cytoplasmic proteins. It is a non-specific drug for the cycle.

The chemical name of this product is: (Z)-diamminedichloroplatinum.

It is a first-line drug for the treatment of various solid tumors. Combination with VP-16 (EP regimen) is a first-line regimen for the treatment of SCLC or NSCLC. Combination with MMC, IFO (IMP regimen), or NVB is a common regimen for the treatment of NSCLC. Combination chemotherapy based on DDP is also the main treatment for advanced ovarian cancer, osteosarcoma and neuroblastoma. Combination with ADM, CTX, etc. is effective for squamous cell carcinoma and transitional cell carcinoma in multiple sites, such as head and neck, cervix, esophagus and urinary system tumors. "PVB" (DDP, VLB, BLM) can treat most stage IV non-spermatogonia testicular cancers with a remission rate of 50% to 80%. In addition, this product is a radiotherapy sensitizer. It is currently widely used in foreign countries for local radiotherapy of stage IV inoperable NSCLC, which can improve efficacy and survival.

1 General dose: 20 mg/m2 per body surface area, once a day, for five consecutive days, or 30 mg/m2 per day, for three consecutive days, and appropriate hydration and diuresis are required. 2 High dose: 80-120 mg/m2 each time, intravenous drip, once every 3-4 weeks, the maximum dose should not exceed 120 mg/m2, 100 mg/m2 is appropriate. To prevent the renal toxicity of this product, sufficient hydration is required: 2000 ml of isotonic glucose solution is dripped intravenously 12 hours before cisplatin (PDD), 3000-3500 ml of isotonic saline or glucose solution is transfused on the day of DDP use, and potassium chloride, mannitol and furosemide (furosemide) are used, and the daily urine volume is 2000-3000 ml. Pay attention to changes in blood potassium and blood magnesium during treatment, and correct low potassium and low magnesium if necessary.

1. Gastrointestinal reactions: severe nausea and vomiting are the main limiting toxicity. Acute vomiting generally occurs 1 to 2 hours after administration and can last for about a week. Therefore, when using this product, it is necessary to use a strong antiemetic, such as 5-hydroxytryptamine 3 (5-HT3), receptor antagonist antiemetic ondansetron, etc., which can basically control acute vomiting; 2. Nephrotoxicity: Cumulative and dose-related poor renal function is the main limiting toxicity of cisplatin. Generally, a daily dose exceeding 90 mg/m2 is a risk factor for nephrotoxicity. It is mainly renal tubular damage. Acute damage is generally seen 10 to 15 days after medication, with increased blood urea nitrogen (BUN) and creatinine (Cr), decreased creatinine clearance, and most of them are reversible. Repeated high-dose treatment can cause persistent mild to moderate renal damage. At present, there is no effective means to prevent nephrotoxicity caused by this product except hydration; 3. Neurotoxicity: Neurological damage such as tinnitus and hearing loss caused by auditory nerve damage are more common. Peripheral neurotoxicity is related to the cumulative dose increase, which is manifested as varying degrees of weakened or lost sensation in the hands and feet, sometimes with extremity paralysis, decreased trunk muscle strength, etc., which are generally difficult to recover. Epilepsy and papilledema or retrobulbar neuritis are less common; 4. Bone marrow suppression: Bone marrow suppression (decreased white blood cells and/or platelets) is generally mild, and the incidence is related to the dose of each course of treatment. If the dose is 100mg/m2, the incidence is about 10-20%, and if the dose is 120mg/m2, it is about 40%, but it is also related to the overlap of bone marrow toxicity of other anticancer drugs in combined chemotherapy; 5. Allergic reactions: facial swelling, asthma, tachycardia, hypotension, and non-specific maculopapular rash may occur; 6. Others: abnormal heart function and liver function changes are rare.

It is contraindicated in patients with renal impairment and pregnant women.

The combined use of aminoglycoside antibiotics, amphotericin B or cephalothin with this product has an additive nephrotoxic effect; MTX and BLM are mainly excreted by the kidneys, and the renal damage caused by this product will delay the excretion of the above two drugs, resulting in increased toxicity. When probenecid is used in combination with this product, it can cause hyperuricemia; chloramphenicol or its furosemide or sodium urate increases the ototoxicity of this product; antihistamines can mask the symptoms of tinnitus, dizziness, etc. caused by this product.

Protect from light and store in a sealed container at room temperature.

10mg

Dezhou Deyao Pharmaceutical Co., Ltd.

• Founded in:

  2003-12-29

• Address:

  No. 6000, Dongfanghong East Road, Economic and Technological Development Zone, Dezhou City, Shandong Province

• Tax NO.:

  9137140075748721XU

• Registered Funds:

  200 million yuan

• Website:

  Log in to view

• Email:

  Log in to view